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Cluster of 
Falciparum 
Malaria Cases in 
UK Airport
Alison J. Rodger,*† Graham S. Cooke,‡§ 
Rosalynn Ord,¶ Colin J. Sutherland,¶ 
and Geoffrey Pasvol*§
A cluster of 6 cases of Plasmodium falciparum malar-
ia occurred in a UK airport among 30 travelers returning 
to the United States from East Africa. Molecular genotyp-
ing analysis indicated that all had been exposed to differ-
ent parasites. The travelers’ use of chemoprophylaxis was 
poor; their perception of risk was limited.
Although most malaria occurs in Africa and Asia, it is also found in travelers returning from malaria-en-
demic regions (1). In the United States in 2005, a total of 
1,528 cases of malaria were diagnosed, an increase of 15% 
from the previous year (2). In the United Kingdom in 2006, 
a total of 1,758 malaria cases were reported (3). In each 
country, malaria prophylaxis was inadequate for 75%–80% 
of patients (2,3).
Most cases of malaria in travelers occur sporadically 
as single cases. We describe a cluster of Plasmodium falci-
parum malaria cases among a group of US citizens return-
ing from East Africa.
The Cases
A group of 30 US citizens spent June and July 2005 in 
Kenya and Uganda as part of an educational program. Their 
return journey took them from Nairobi to London, where 
they spent a week before their fl ight to the United States. 
By the time they arrived at the airport departure lounge, 6 
persons had become sick with high fevers, rigors, and some 
confusion. They were referred by airport staff to the Infec-
tious Diseases Unit at Northwick Park Hospital, London.
All arrived at the unit within 3 hours of referral and 
were proven to have falciparum malaria on peripheral blood 
smears. Clinical features of persons with disease are shown 
in the Table. Of these 6 persons, all were 19–22 years of 
age, and 5 exhibited initial clinical features of severe ma-
laria, e.g., impaired consciousness (disorientation as to 
time, place, or person; or prostration [inability to sit up and 
drink]). These 5 persons required intravenous quinine and 
intensive monitoring; the other person had less severe dis-
ease and was treated with a combination of oral atovaquone 
and proguanil. All improved by day 4 and returned to the 
United States shortly thereafter.
In light of these cases, all other members of the group 
who had returned to the United States were alerted to con-
tact their healthcare providers if they became symptomatic. 
Another person became febrile while in the United States 
and was initially treated with conventional antimicrobial 
drugs; this person was later recalled to a hospital and treat-
ed appropriately for falciparum malaria after the diagno-
sis of his colleagues became known. Unconfi rmed reports 
were received that 2 more patients had received treatment 
for malaria (species unidentifi ed) within 6 months of re-
turn. The high attack rate in this group of students and the 
close temporal clustering of cases led us to examine the 
possibility that the group had experienced a mini-outbreak 
as a result of a point-source exposure.
A study-specifi c, self-administered questionnaire gath-
ered information about demographics, onset and nature of 
symptoms, medical history, malaria protective measures, 
and chemoprophylaxis and adherence. The questionnaire 
was given to patients 1–6 in the UK hospital and to patient 
7 by email. Clinical data for patients 1–6 were obtained 
during their UK hospital stay, and clinical data for patient 7 
was obtained from the diagnosing and treating physician in 
the United States. Genetic diversity of parasite isolates was 
investigated by PCR amplifi cation of polymorphic regions 
of the P. falciparum merozoite surface protein 1 (Pfmsp1) 
and Pfmsp2 loci as previously described (5).
The group had traveled together through Kenya and 
Uganda, with almost identical itineraries. All had slept 
in shared accommodations under unimpregnated malaria 
nets. Despite weekly malaria education sessions, antima-
larial drug use was not widespread in the absence of a clear 
predeparture recommendation. Only 1 of 7 patients had 
taken malaria prophylaxis, but this person did not continue 
using chemoprophylaxis for the full period at risk. None of 
the 7 patients recalled being bitten by mosquitoes. How-
ever, when returning to Nairobi on July 2, 2005, the group 
was delayed for several hours by the roadside in the rice-
growing area of Mwea (northern Kenya). Many had little 
protective clothing with them and while waiting until dusk 
that evening, noticed a large number of mosquitoes of un-
known species around them. This event occurred 20 days 
before fi rst onset of symptoms. After visiting Uganda, the 
group returned to Nairobi on July 11, arrived in London on 
July 13, and went to London’s Heathrow Airport on July 20 
for the fl ight back to the United States.
Paired peripheral blood samples from pretreatment 
and day 1 posttreatment were provided by 6 of the 7 pa-
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tients; for the other patient, only a pretreatment sample was 
available for DNA analysis. No 2 patients had identical al-
leles at both Pfmsp1 and Pfmsp2 loci (Figure). At least 12 
different parasite genotypes were detected. Pretreatment 
and posttreatment samples were similar except for those of 
patient 2, for whom postquinine allelic patterns differed for 
Pfmsp1 and Pfmsp2 on day 1 and day 0.
Conclusions
Malaria-endemic areas, such as East Africa, are in-
creasingly popular destinations for US travelers. There-
fore, suboptimal adherence to malaria chemoprophylaxis 
and effective preventative measures against mosquito bites 
(such as use of bed nets) is cause for concern (3). Anti-
malarial drug use was poor among the case-patients, for 
whom emphasis was placed on personal protective mea-
sures rather than chemoprophylaxis. The high attack rate 
for this group is consistent with rates reported by other 
studies demonstrating the injudicious risk of traveling to a 
malaria-endemic area without taking effective antimalarial 
drugs (6,7).
The course of disease for patients 1–6 displayed re-
markable synchrony; onset of symptoms occurred within 
24 hours of each other and illness proceeded rapidly. These 
6 patients received prompt diagnosis and treatment at a 
specialist unit and recovered fully. Had it had not been for 
alert airport staff, these 6 patients (5 with severe malaria) 
would have been on a 9-hour fl ight to the United States; 
consequences for the patients could have been fatal. These 
cases highlight the benefi ts of vigilant staff at airports, 
even for passengers boarding from non–disease-endemic 
areas. Prompt contact tracing enabled a missed diagnosis 
of malaria to be rectifi ed at a US facility and highlights 
the advantage of actively seeking all those who might have 
shared the same exposure.
The clustering of the onset of symptoms for patients 
1–6 suggested a common timing of infection, although 
other unproven factors, such as the effect of atmospheric 
pressure changes during air travel, may have led to the syn-
chronous onset of the cases. Molecular evidence suggests 
that despite synchrony of symptoms, the genetically het-
erogeneous parasite variants were unlikely to have come 
from 1 infectious mosquito. We estimate that at least 12 
distinct haploid parasite genotypes were circulating among 
the 6 patients. Our data also demonstrate, for patient 2, 
that circulating parasite genotypes can change profoundly 
immediately after treatment, as previously observed for 
quinine-treated persons (8). Caution is therefore required 
when interpreting genotyping data for treated persons (9).
The only reported intense exposure to mosquitoes was 
during the travel delay in Mwea. The main rice-growing 
season starts in June, which is also the time of Anopheles 
spp. peak abundance (10). However, the mosquitoes seen 
at Mwea were not positively identifi ed as Anopheles, and 
although the students did not recall being bitten by mosqui-
toes on other occasions, we cannot rule out infection later 
in the journey, which would be more probable given the 
date of onset of symptoms in nonimmune persons.
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Figure. Molecular typing of malarial parasites from 6 US travelers with 
falciparum malaria returning from East Africa in 2005. Plasmodium 
falciparum merozoite surface protein 1 (Pfmsp1) (upper gel) and 
Pfmsp2 (lower gel) allelic variation among isolates was determined 
by nested PCR and agarose gel electrophoresis. DNA markers 
(MW) are in lanes 1 and 13 in each gel. Two family-specifi c primer 
sets were used for each of the 2 genes. No parasites of the Ro33 
allelic family of msp1 were found (data not shown). Pretreatment 
(day 0) isolates are shown for all patients. Posttreatment (day 1) 
parasite isolates are also shown for patients 2–6.
Table. Clinical data for 6 US travelers with falciparum malaria returning from East Africa, 2005* 
Patient
no.
Malaria
severity (4) Temp, °C BP, mm Hg Parasitemia, % HGB† Platelets‡ Creatinine§ Bilirubin¶ ALT#
Base
excess** 
1 Severe 38.2 97/52 3.5 9.3 33 89 71 103 –2.4
2 Severe 40.1 132/73 3.5 16.0 38 108 40 101 3.1
3 Mild 38.0 110/75 1.0 13.3 48 70 20 34 ND
4 Severe 36.4 99/63 3.5 16.5 193 111 22 34 –2.3
5 Severe 39.4 105/72 1.5 16.8 121 103 20 38 -0.8
6 Severe 37.8 79/53 1.0 13.1 54 102 9 41 –4.8
*Date of symptom onset for each patient was 2005 Jul 20. Temp, body temperature; BP, blood pressure; HGB, hemoglobin; ALT, alanine
aminotransferase; ND, not done. 
†Reference range 11–15 g/dL. 
‡Reference range 120–308 × 109/L. 
§Reference range <100 Pm/L. To convert to mg/dL, divide by 88.4. 
¶Reference range <19 Pm/L. To convert to mg/dL, divide by 17.1. 
#Reference range 19–50 U/L. 
**In mmol/L. To convert to mEq/L, divide by 1.0. 
msp1 K1 family of alleles
01 02 03 04 05 06 01 02 03 04 05 06
msp1 MAD20 family of alleles
MW MW
msp2 IC allelesmsp2 FC27 alleles
This mini-outbreak demonstrates the need to encour-
age travelers to take malaria prophylaxis and to improve 
their knowledge about the risk of malaria in their area of 
proposed travel. It also underscores the value of alerting 
fellow travelers in the same party to the possibility of con-
tracting malaria.
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